References
- Agardh C-D, Nilsson-Ehle P, Lundgren R, Gustavs-Son A. The influence of treatment with estrogens and estramustine phosphate on platelet aggregation and plasma lipoproteins in non-disseminated prostatic carcinoma. J Urol 1984; 132: 1021–1024
- Bailar J C, III, Byar D P, The Veterans Administration Cooperative Urological Research Group. Estrogen treatment for cancer of the prostate: early results with 3 doses of diethylstilbestrol and placebo. Cancer 1970; 26: 257–261
- Benson R C, Jr. Estramustine phosphate as primary therapy for metastatic prostate cancer. Preliminary results of the University of Wisconsin trial. Urology 1984; 6: 69–72, Suppl to vol 23
- Björk P, Forsgren B, Gustavsson J-Å, Pousette Å, Högberg B. Partial characterization and “quantitation” of a human prostatic estramustine-binding protein. Cancer Res 1982; 42: 1935–1942
- Blackard C E. The Veterans Administration Cooperative Urological Research Group's studies of carcinoma of the prostate: A review. Cancer Chemotherapy Rep 1975; 59: 225–227
- Byar D P. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126–1130
- Esposti P L. Cytological malignancy grading of prostatic carcinoma by transrectal aspiration biopsy. Scand J Urol Nephrol 1971; 5: 199–209
- Forsgren B, Björk P, Carlström K, Gustavsson J-Å, Pousette Å, Högberg B. Purification and distribution of a major protein in rat prostate that binds estramustine, a nitrogen mustard derivate of estratiol 17 — β. Proc Natl Acad Sci USA 1979; 76: 3149–3153
- Franzén S, Giertz G, Zajicek J. Cytological diagnosis of prostatic tumors by transrectal aspiration biopsy. A preliminary report. Br J Urol 1960; 32: 193–196
- Fritjofsson Å, Norlén B J, Högberg B, Rajalakshmi M, Cekan S Z, Diczfalusy E. Hormonal effects of different doses of estramustine phosphate (Estracyt®) in patients with prostatic carcinoma. Scand J Urol Nephrol 1981; 15: 374
- Fritjofsson Å, Björk P, Gunnarsson P O, Norlén B J. Binding and accumulation of active metabolites in tumours from prostatic cancer patients treated with Estracyt. Preliminary report. Proceedings of the 13th International Congress of Chemotherapy. Vienna 1983
- Hartley-Asp B. Estramustine induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. The Prostate 1984; 5(1)93–100
- Hedlund P O, Gustavsson H, Sjögren S. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. Scand J Urol Nephrol 1980; 55: 103–105, Suppl
- Huggins C, Hodges C V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297
- Huggins C, Stevens R E, Hodges C V. Studies on prostatic cancer. II. Effects of castration on advanced carcinoma of prostate gland. Arch Surg 1941; 43: 209–223
- Jonsson G, Olsson A M, Luttropp W, Cekan Z, Purvis K, Diczfalusy E. Treatment of prostate carcinoma with various type of estrogen derivates. Vitamin and Hormones 1975; 33: 351–376
- Miller G J, Miller N E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 4: 16–19
- Rössner S, Hedlund P-O, Jogestrand T, Säwe U. Treatment of prostatic cancer. Effects on serum lipoproteins and the cardiovascular system. J Urol 1985; 133: 53–57
- Shearer R J, Hendry W F, Sommerville I F, Fergusson J D. Plasma testosterone: An accurate monitor of hormone treatment in prostatic cancer. Br J Urol 1973; 45: 668–677
- Smith P H, Robinson M, Richards B, Sucio S, De Pauw M, Sylwester R, Denis L, EORTC Urological Group. Estramustine phosphate in prostate cancer EORTC experience: Preliminary results of protocol 30762. Urology 1984; 6: 64–68, Suppl to vol. 23
- Tew K D. The mechanism of action of estramustine. Sem Oncol 1983; 3(10)21–26, Suppl
- The Veterans Administration Cooperative Urological Research Group. Carcinoma of the prostate: Treatment comparisons. J Urol 1967; 98: 516–522